Octant Secures FDA Orphan Status for Its Retinitis Pigmentosa Drug

Octant, Inc. announced on October 27, 2026, that the U.S. Food and Drug Administration (FDA) had granted Orphan Drug Designation to OCT-980 for retinitis pigmentosa (RP), including rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP), the specific indication for which the candidate is being developed.

OCT-980 is an investigational oral small molecule designed to correct rhodopsin protein misfolding and restore its appropriate cellular trafficking. The candidate is currently being evaluated in a Phase 1/2 clinical study. The designation provides development incentives for a programme targeting a rare inherited retinal disorder but does not establish clinical efficacy or guarantee regulatory approval.

OCT-980 Targets the Underlying Protein Defect

Retinitis pigmentosa comprises a group of inherited retinal disorders characterised by progressive vision loss that can ultimately lead to blindness. In RHO-adRP, disease-associated variants in the rhodopsin (RHO) gene can cause the protein to misfold or traffic incorrectly within photoreceptor cells, disrupting cellular function and contributing to progressive retinal degeneration.

OCT-980 is designed to address this protein-processing defect rather than manage symptoms alone. By correcting rhodopsin misfolding and restoring appropriate cellular trafficking, the candidate aims to preserve visual function and potentially slow disease progression.

However, the proposed mechanism remains a therapeutic hypothesis to be tested clinically. Octant has not reported evidence from the ongoing patient study demonstrating that OCT-980 improves vision or slows retinal degeneration.

Phase 1b/2 Study Moves Evaluation into Patients

The OCT-980 programme is being evaluated in an integrated first-in-human Phase 1/2 study (NCT07408232). The Phase 1a component in healthy volunteers has been completed, while the Phase 1b/2 component is evaluating the candidate in patients with genetically confirmed RHO-adRP.

Octant announced the first patient dose in the Phase 1b/2 study on September 24, 2026. The patient study is designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics and potential efficacy, including measures of retinal structure and visual function. The open-label, multiple-ascending-dose design will help characterise the candidate’s effects during early clinical development.

The transition into patients is an important milestone because findings from laboratory studies and healthy volunteers cannot establish whether the proposed mechanism translates into meaningful clinical benefit. The study must determine whether OCT-980 can be administered at tolerable doses and whether its biological activity is accompanied by measurable changes relevant to vision.

The early-stage study is not, by itself, expected to establish definitive efficacy. Its findings will need to be interpreted in the context of the small patient population, variability in disease progression and the limitations of an open-label design.

FDA Designation Provides Conditional Development Incentives

The FDA’s Orphan Drug Designation programme supports the development of treatments for rare diseases. Eligible sponsors may receive tax credits for qualified clinical trials, exemptions from certain FDA application fees and eligibility for seven years of U.S. orphan-drug exclusivity following approval, subject to applicable requirements.

For Octant, these incentives may support the economics of advancing OCT-980 through clinical development. However, the designation is separate from marketing approval and does not establish that the candidate is safe or effective. Any future application would require the necessary clinical evidence and regulatory review.

Octant’s broader discovery platform, The Navigator, combines high-throughput synthetic biology, generative chemistry and artificial intelligence and machine learning to develop therapies targeting complex cellular mechanisms. OCT-980 is one of its programmes focused on protein-misfolding disorders.

Clinical Interpretation

The FDA designation provides regulatory support for OCT-980 as Octant advances its investigation of an oral treatment targeting rhodopsin misfolding in RHO-adRP. The candidate’s mechanism offers a distinct development strategy, but its clinical relevance remains uncertain until patient data establish acceptable safety and evidence of therapeutic activity.

The next meaningful milestone will be clinical findings from the ongoing Phase 1b/2 study. These results will determine whether correcting rhodopsin misfolding can translate into measurable effects on retinal structure or visual function. Until such evidence emerges, OCT-980 remains an investigational candidate rather than an established disease-modifying treatment.

Reference

Octant Receives FDA Orphan Drug Designation for OCT-980 for the Treatment of Retinitis Pigmentosa, Octant, 27 October 2026

A Phase 1/​2 Study in Healthy Volunteers and Participants with Autosomal Dominant Retinitis Pigmentosa (RHO-adRP), ClinicalTrials.gov ID NCT07408232

Octant Announces First Patient Dosed in Phase 1b/2 Clinical Study of OCT-980 for the Treatment of Retinitis Pigmentosa, Octant, 24 September 2026